Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
A radiolabeled monoclonal antibody targeting tumor antigen B7-H3 in development for intraventricular radioimmunotherapy for treatment of neuroblastoma central nervous system/leptomeningeal metastases.
This report evaluates the analytical validity, clinical validity, and clinical utility of the ChemoFx test, an in vitro patient tumor–derived cell culture assay that determines how cancer cells may respond to chemotherapeutic agents in order to help guide physicians’ treatment decisions in patients with gynecologic cancer.
Inclisiran is a subcutaneously administered, investigational RNAi therapeutic that decreases hepatic synthesis of proprotein convertase subtilisin kexin type 9 (PCSK9), leading to increased low-density lipoprotein (LDL) receptor expression on the hepatocyte cell surface and subsequently to greater removal of LDL-C from circulation.
Oxlumo (lumasiran) is a subcutaneously injected, HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Dosing is weight-based; for children weighing less than 10 kg, the recommended maintenance dose is 3 mg/kg once monthly. Dosing for individua…
Focus of the Report: Transperineal template prostate (TTP) biopsy is an alternative to standard transrectal ultrasound (TRUS) biopsy for repeat biopsies. TTP biopsy is a form of saturation biopsy (at least 20 cores) that uses a brachytherapy grid to assure even distribution of the cores.
Tec…
Lisocabtagene maraleucel (liso-cel) is an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is proposed to treat adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies.
Focus of the Report: This health technology assessment focuses on the use of t:slim X2 Insulin Pump and Dexcom 6 continuous glucose monitoring (CGM) with Control-IQ closed-loop control (CLC) or Basal-IQ predictive low-glucose suspend (PLGS) technology for the management of diabetes mellitus (DM).
read more
Sutimlimab is an intravenous monoclonal antibody targeting complement component 1s (C1s) for the treatment of cold agglutinin disease.
Narsoplimab is an investigational, intravenous monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).
Focus of the Report: This report focuses on Lee Silverman Voice Treatment (LSVT) LOUD for the treatment of patients with speech and voice problems resulting from Parkinson disease (PD).
Technology Description: LSVT LOUD is an intensive voice therapy regimen that requires high patient e…